← back to search

Hao Li

Nanchang University · CN
Area of research
Surgery · Otorhinolaryngology
Research interest
Research interests include Head and Neck Cancer Studies, Thyroid Cancer Diagnosis and Treatment, Salivary Gland Tumors Diagnosis and Treatment, and Cancer Immunotherapy and Biomarkers.
h-index
26
citations
2,664
works
214
NIH funding
primary concept
email

Recent publications

Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma
JAMA 2025cited by 53position: middledoi
Development and validation of a deep learning-based pathomics signature for prognosis and chemotherapy benefits in colorectal cancer: a retrospective multicenter cohort study
Frontiers in Immunology 2025cited by 2position: middledoi
A TRIM21–UCHL3–ITCH–SIPA1 axis promotes colorectal cancer growth and metastasis
Cancer Letters 2025cited by 1position: middledoi
Development and validation of a deep learning–based pathomics signature for prognosis and chemotherapy benefits in colorectal cancer: A retrospective multicenter cohort study.
Journal of Clinical Oncology 2025cited by 1position: middledoi
Deep Learning-Based Pathomics Signature Predicts Prognosis and Treatment Response in Gastric Cancer: A Multicenter Retrospective Study
SSRN Electronic Journal 2025cited by 1position: middledoi
Disruption of cellular plasticity by repeat RNAs in human pancreatic cancer
Cell 2024cited by 22position: middledoi
Transcatheter arterial chemoembolization plus apatinib with or without camrelizumab for unresectable hepatocellular carcinoma: a multicenter retrospective cohort study
Hepatology International 2023cited by 33position: middledoi
Transarterial chemoembolization combined donafenib with/without PD-1 for unresectable HCC in a multicenter retrospective study
Frontiers in Immunology 2023cited by 18position: firstdoi
C5aR antagonist inhibits LPS-induced inflammation in human gingival fibroblasts via NF-κB and MAPK signaling pathways
Journal of Applied Oral Science 2023cited by 3position: middledoi
Comparison of efficacy and safety of neoadjuvant regimens for resectable esophageal squamous cell carcinoma: A meta-analysis.
Journal of Clinical Oncology 2023cited by 1position: middledoi
A Potential Indicator ARRDC2 Has Feasibility to Evaluate Prognosis and Immune Microenvironment in Ovarian Cancer
Frontiers in Genetics 2022cited by 7position: middledoi
Corrigendum: A potential indicator ARRDC2 has feasibility to evaluate prognosis and immune microenvironment in ovarian cancer
Frontiers in Genetics 2022cited by 2position: middledoi
[The effectiveness of different respiration models to the amplitude of waveform information in arterial blood gas].
PubMed 2021cited by 1position: middledoi
[Preliminary report on partial pressure changes of oxygen and carbon dioxide in umbilical artery and vein before and after the first breath in Chinese neonates II-The personalized analysis of partial pressure of oxygen and carbon dioxide difference between umbilical artery and vein at same time in same newborn].
PubMed 2021cited by 0position: middledoi
Trends in clinical features and survival of oral cavity cancer: fifty years of experience with 3,362 consecutive cases from a single institution
Cancer Management and Research 2018cited by 68position: middledoi
Treatment of Intercondylar Humeral Fractures With 3D-Printed Osteosynthesis Plates
Medicine 2016cited by 81position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Huiying Li · Harbin Medical University4 papers (2025–2025)Shenghan Lou · Harbin Medical University4 papers (2025–2025)Gary Mo · Eli Lilly (United States)4 papers (2025–2025)Peng Han · Chinese PLA General Hospital3 papers (2025–2025)Haonan Xie · Harbin Medical University3 papers (2025–2025)Fenqi Du · Harbin Medical University3 papers (2025–2025)Yuze Huang · Harbin Medical University3 papers (2025–2025)Rong Chen · Huaqiao University2 papers (2021–2021)Yong Wang · Shenyang Pharmaceutical University2 papers (2023–2023)Can Wang · Nanjing University of Chinese Medicine2 papers (2022–2022)Fang Liu · North Sichuan Medical University2 papers (2021–2021)Hang Wang · Tongji University2 papers (2025–2025)Yuanchun Li · The Affiliated Yongchuan Hospital of Chongqing Medical University2 papers (2025–2025)Xing‐Guo Sun · Dalian Medical University2 papers (2021–2021)Mengjun Zhang · Harbin Medical University2 papers (2022–2022)Yan Cui · Ericsson (Sweden)2 papers (2021–2021)Guizhi Wang · Anhui University2 papers (2021–2021)Wenjie Song · Harbin Medical University2 papers (2025–2025)Yan Huang · Wuhan University2 papers (2021–2021)Xuhua Duan · Union Hospital2 papers (2023–2023)